



Genomics and gene therapy
Somatic mutations in lymphocytes in patients with
immune-mediated aplastic anemia
Sofie Lundgren 1,2 ● Mikko A. I. Keränen1,2,3 ● Matti Kankainen 1,2,4 ● Jani Huuhtanen 1,2,5 ● Gunilla Walldin6 ●
Cassandra M. Kerr7 ● Michael Clemente7 ● Freja Ebeling3 ● Hanna Rajala1,2,3 ● Oscar Brück 1,2 ● Harri Lähdesmäki5 ●
Sari Hannula8 ● Tiina Hannunen8 ● Pekka Ellonen8 ● Neal S. Young9 ● Seishi Ogawa10 ● Jaroslaw P. Maciejewski 7 ●
Eva Hellström-Lindberg6 ● Satu Mustjoki 1,2,11
Received: 4 September 2020 / Revised: 4 February 2021 / Accepted: 12 March 2021 / Published online: 30 March 2021
© The Author(s) 2021. This article is published with open access
Abstract
The prevalence and functional impact of somatic mutations in nonleukemic T cells is not well characterized, although clonal
T-cell expansions are common. In immune-mediated aplastic anemia (AA), cytotoxic T-cell expansions are shown to
participate in disease pathogenesis. We investigated the mutation profiles of T cells in AA by a custom panel of 2533 genes.
We sequenced CD4+ and CD8+ T cells of 24 AA patients and compared the results to 20 healthy controls and whole-
exome sequencing of 37 patients with AA. Somatic variants were common both in patients and healthy controls but enriched
to AA patients’ CD8+ T cells, which accumulated most mutations on JAK-STAT and MAPK pathways. Mutation burden
was associated with CD8+ T-cell clonality, assessed by T-cell receptor beta sequencing. To understand the effect of
mutations, we performed single-cell sequencing of AA patients carrying STAT3 or other mutations in CD8+ T cells. STAT3
mutated clone was cytotoxic, clearly distinguishable from other CD8+ T cells, and attenuated by successful
immunosuppressive treatment. Our results suggest that somatic mutations in T cells are common, associate with clonality,
and can alter T-cell phenotype, warranting further investigation of their role in the pathogenesis of AA.
Introduction
Acquired aplastic anemia (AA) is an immune-mediated
bone marrow failure syndrome in which cytotoxic T cells
mediate the destruction of hematopoietic stem and
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progenitor cells (HSPCs) [1–3]. Characteristic features of
immune-mediated AA are clonal alterations in HSPCs: X-
chromosome skewing [4], cytogenetic abnormalities [5, 6],
uniparental disomy of the 6p [7], somatic phosphatidyli-
nositol glycan class A gene mutations leading to parox-
ysmal nocturnal hemoglobinuria [8], and somatic mutations
in genes related to clonal hematopoiesis (CH) [9–14]. It has
been suggested that some clonal changes in target cells are
enriched by selective pressure from autoreactive T cells, and
hence they may serve as an immune escape mechanism
[1, 15].
Oligoclonal CD8+ T cells are frequently detected in AA
and they are able to induce apoptosis of autologous HSPC
[16, 17]. Furthermore, T cells in AA patients are known to
be aberrantly active [18–20], but their antigenic target on
HSPC remains unknown.
Previously, we and others have detected somatic muta-
tions in T cells in patients with various immune-mediated
disorders: newly diagnosed rheumatoid arthritis [21], Fel-
ty’s syndrome [22], pure red cell aplasia [23], multiple
sclerosis [24, 25], chronic graft-versus-host disease [26],
and T-cell large granular lymphocytic (T-LGL) leukemia
[27–29]. In T-LGL leukemia and Felty’s syndrome acti-
vating STAT3 mutations in CD8+ T cells are the hallmark
of the disease, but STAT3 mutations have also been dis-
covered in 11% of AA patients [30].
Although the role of somatic events in lymphocytes is
not known in detail in patients with autoimmune diseases,
they may alter the lymphocyte phenotype and function, and
in that manner contribute to the pathogenesis. Mutations
may either arise de novo in mature lymphocytes during cell
division or mutations of CH may drift to lymphocytes,
which is a phenomenon called lympho-myeloid CH
[31, 32]. In the current study, we characterized the spectrum
of somatic mutations in T cells in patients with AA. Fur-
thermore, we evaluated their origins and described their
potential impact on single-cell resolution at the diagnosis,
relapse, and the recovery of AA.
We show that somatic mutations in T cells are common
in AA and even in healthy individuals. These findings
extend our understanding of the presence of somatic
mutations in nonmalignant diseases and provide basis for
the further development of novel therapeutic and diagnostic
approaches in lymphocyte-mediated autoimmune diseases.
Methods
Samples analyzed by immunogene panel
sequencing
Peripheral blood and bone marrow were collected from
patients suffering from immune-mediated AA (n= 24), see
Table S1 for clinical characteristics of the cohort. Patients
were recruited from the Department of Hematology in the
Helsinki University Hospital and from other participating
university hospitals (Karolinska Institute, Sweden, and
Cleveland Clinic, Cleveland, OH, USA). This study was
approved by the local Ethics Committees, and the princi-
ples of Helsinki Declaration were followed. All patients
had given their written informed consent before sample
collection. Age-matched healthy blood donor buffy
coats were provided by Finnish Red Cross Blood Service
(n= 20).
Diagnosis of AA
The diagnosis of immune-mediated AA was based on
hypocellular (cellularity < 30%) bone marrow and exclusion
of constitutional genetic defects and chemical and physio-
logical damage. The severity was based on Camitta’s cri-
teria [33]. Moderate AA was defined as decreased bone
marrow cellularity and cytopenias not qualifying for severe
AA and exclusion of other causes.
Sample preparation and immunogene panel
sequencing
Sample preparation and immunogene panel sequencing of
CD4+ and CD8+ T cells was performed as previously
described [34]. A custom gene panel based on 2533 can-
didate genes along pathways important in innate and
adaptive immunity was used. See Supplementary Methods
for further information. The sequencing was performed at
the Institute for Molecular Medicine Finland, HiLIFE.
Other genomic datasets
We analyzed raw whole-exome sequencing (WES) data
from a previously published dataset of 37 AA patients from
Yoshizato et al. [13]. In our analysis, we included CD3−
and CD3+ sample from each patient. We also utilized raw
WES data from skin samples of nine AA patients,
sequenced as described previously [27]. WES data from
skin samples were used as a part of panel of normals (PON)
for filtering variants detected with WES and immunogene
panel sequencing (see Supplementary Methods).
All cohorts used in somatic variant analysis are sum-
marized in Table 1 and study design is illustrated in Fig. S1.
Identification and analysis of potentially pathogenic
somatic variants
All datasets were processed and analyzed according to a
previously described GATK practice [35], see Supple-
mentary Methods for more detailed description. Following
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this processing, a joint recalling of newly detected variants
and known hotspot variants (listed in Table S2) across all
samples was done by running MuTect2 in genotyping
mode. Variants detected in both CD4+ and CD8+ T cells
of same patient were interpreted as lymphoid precursor
(LP) variants, and the rest of the variants were categorized
as CD8+ and CD4+ specific variants (list of detected
variants in Table S3). Adjusted somatic mutation burden
and mutational signatures were calculated and variant
effects were predicted as described in Supplementary
Methods.
Amplicon validation
Amplicon sequencing was performed to validate a selected
set of mutations found in the immunogene panel sequencing
(Table S4). Details of amplicon sequencing and analysis are
provided in Supplementary Methods.
Analysis of clonal T-cell populations
Sorted CD8+ T-cell fractions of available samples were
analyzed with a multiplexed PCR assay that targets the
variable CDR3 region of the rearranged TCRβ locus [36].
Next-generation sequencing was performed, and data were
analyzed with the ImmunoSEQ analysis tools provided by
Adaptive Biotechnologies. Clonality was calculated as 1−
Shannon’s entropy for all rearrangements [37]. TCR Vβ
family based flow cytometry and sorting are described in
Supplementary Methods.
Single-cell gene expression and V(D)J transcript
profiling and data analysis
Frozen MNC from PB or BM were sorted with BD Influx
Cell sorter and the gene and V(D)J transcript profiles were
studied with 10X Genomics Chromium Single Cell V(D)J
and 5′ Gene Expression platform. A detailed description of
sample processing and sequencing is provided in Supple-
mentary Methods and Fig. S2.
Detailed description of bioinformatic analyses is provided
in Supplementary Methods and Figs. S3–S5. Tables S5 and
S6 contain lists of differentially expressed genes used in
cluster annotation.
Statistical testing
Due to non-Gaussian data distributions, nonparametric tests
were used, including Mann–Whitney U test in comparisons
between two groups, Kruskal–Wallis in comparisons
between three or more groups and Spearman’s rank test in
correlation with R (3.6.0).
Results
Clonal CD8+ T-cell populations are associated with
increased somatic mutation burden
We performed immunogene panel deep sequencing of CD4+
and CD8+ T cells from 24 AA patients and 20 healthy
controls (age median [range], respectively: 63 [23–84] and 61
[44–66], Fig. S6). Mean sequencing depth was 299x [249x
for AA and 359x for healthy samples] (Fig. S7A, B). We
divided the variants to three categories: CD4+ specific or
CD8+ specific variants (detected only in CD4+ or CD8+
T cells) and LP variants (detected in both CD4+ and CD8+
T cells, see “Methods”). We detected altogether 731 somatic
variants in 519 genes in patients and healthy, with mean
[median] of 8.3 [7] variants per sample (1.46 [1.22] variants/
Mb) and mean variant allele frequency (VAF) of 4.5%
(Fig. 1A). Nonsynonymous variants were enriched in AA
patients compared to healthy controls (frequencies of non-
synonymous variants from all variants were 74.8% and
68.8% respectively, p= 0.058). The VAFs of CD4+ and
CD8+ specific variants were not significantly different in AA
patients (Fig. S7C). The complete list of variants discovered
by the immunogene panel sequencing is presented in
Table S3, and all nonsynonymous variants including their
VAFs in individual patients are shown in Fig. S8.




Immunogene panel sequencing of immune-
mediated AA patients
24 To investigate somatic mutations in T cells
Immunogene panel sequencing of healthy
individuals
20 PON for immunogene panel samples and comparison of adjusted mutation
burden for AA samples
Skin WES of patients with AA 9 PON for WES samples and immunogene panel samples
CD3+ and CD3− MNC WES of patients with
AA [13]
37 To compare CH derived mutations with somatic mutations seen in T cells
AA aplastic anemia, PON panel of normals, WES whole-exome sequencing, MNC mononuclear cell, CH clonal hematopoiesis.
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Adjusted somatic mutation burden (see Supplementary
Methods) was the highest in CD8+ T cells in patients with
AA (Fig. 1B). Both in AA and healthy controls, CD4+ cells
had a lower mutation burden than CD8+ T cells (median
for each group after outlier removal: AA CD8 1.53, AA
CD4 0.87, healthy CD8 0.78, healthy CD4 0.65, Fig. 1B).
In pairwise comparisons, AA CD8+ T cells had a sig-
nificantly higher mutation burden compared to AA CD4+
T cells (p= 0.029). The number of variants detected in each
sample did not correlate with sequencing depth (ρ=−0.15,
p= 0.27, Fig. S7B).
We validated a selected set of mutations with amplicon
sequencing, as shown in Table S4. Of 15 variants detected
with immunopanel sequencing, 14 were confirmed with
amplicon sequencing in at least one sample, if several
samples from same patient were tested.
The T-cell clonality index for each CD8+ T-cell sample
(see “Methods”) was defined using TCRB sequencing. The
Fig. 1 Variant allele frequency
and adjusted somatic mutation
burden. A Density plot of
variant allele frequencies of CD4
+ and CD8+ specific variants
detected with immunogene panel
sequencing. B Fraction-specific
somatic mutation burden
in AA and healthy samples.
Mann–Whitney U test was used
in pairwise comparisons within
each disease group and cell
fraction, only statistically
significant (p < 0.05) differences
are marked. C Mutation burden
in CD8+ T cells was associated
with T-cell clonality (Spearman
ρ= 0.44, p= 0.012). Each group
is shown separately on the left
panel (Spearman test values for
AA: ρ= 0.71, p= 0.012;
healthy: ρ= 0.21, p= 0.37).
D Number of somatic mutations
in CD8+ T cells did not have
significant correlation with age at
sample collection, although a
positive trend was observed.
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adjusted somatic CD8+ mutation burden significantly cor-
related with CD8+ T-cell clonality (ρ= 0.44, p= 0.012)
but not with patient age (ρ= 0.22, p= 0.16) (Fig. 1C, D),
despite a positive trend was observed with age and fraction-
specific mutation burden in both CD8+ and CD4+ T cells
(Fig. 1D, Fig. S9). When examined separately, a strong
correlation was observed between the mutation load and
cytotoxic T-cell clonality in AA but not in healthy controls
(AA CD8 ρ= 0.71, p= 0.012, Fig. 1C).
Somatic mutations in T cells accumulate into key
immune regulatory pathways
CD8+ T cells in patients with AA harbored most poten-
tially pathogenic variants affecting the JAK-STAT signal-
ing (Fig. 2A, B) and MAPK signaling pathways (Fig. S10),
annotated by Kyoto Encyclopedia of Genes and Genomes
(KEGG) [38]. Mutations in these pathways were also
detected in CD4+ T cells of AA patients.
Fig. 2 CD4+ or CD8+ specific
somatic mutations in JAK-
STAT pathway genes in AA
patients. AMean target coverage
of each sample is presented
in the top panel. Variants on
homopolymer regions are marked
with white dots. B Mutations
marked on JAK-STAT signaling
pathway based on KEGG
database [38], complemented
with closely related MAPK-Erk
and PI3K-Akt-mTOR pathways.
Patients with homopolymer
region variants are colored
with blue. Patients with
pathogenic-predicted variants
are marked with an asterisk (*).
C Mutational signatures from
pooled CD4+ and CD8+ T-cell
somatic variants from each
patient group.
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JAK-STAT pathway mutations (in CD8+ or CD4+
T cells) were detected in 75% of AA patients (18/24) and
40% of healthy controls (8/20) (Fig. 2A, B, Fig. S11). The
frequency of patients with CD4+ or CD8+ specific JAK-
STAT pathway mutations was higher in AA than in healthy
controls (p= 0.031). In CD8+ T cells, JAK1 and STAT3
were recurrently mutated (both 8.3%, 2/24 AA patients’
CD8+ T cells). STAT3 mutations were only observed in AA
patients’ CD8+ T cells. Both STAT3 mutations were p.
Y640F, which is a known mutation hotspot in STAT3 exon
21 [27, 39]. JAK1 mutations were in contrast detected in
both CD4+ and CD8+ T cells and across patient and
healthy groups. All JAK1 mutations were located in
homopolymer regions (Fig. 2A, homopolymer regions
marked with white dots), known to be challenging in NGS
based variant analysis.
The variant effects were predicted as described in Sup-
plementary Methods. In the JAK-STAT pathway, genes
with damaging-predicted mutations in immune-mediated
AA patients included IFNG, JAK3, PTPN11, STAT3, AKT2,
IL2, and PTPN2 (Fig. S11). We discovered only one
damaging-predicted CD4+ or CD8+ specific JAK-STAT
pathway mutation per sample in AA patients.
Potentially pathogenic CD4+ or CD8+ specific MAPK
signaling pathway variants were detected in 88% of AA
patients (21/24). Also, 75% of healthy controls had CD4+
or CD8+ specific variants in MAPK signaling pathway.
Recurrently mutated genes in immune-mediated AA
patients included ARRB2, CACNA1A, FLNB, NLK, and
PPP3CC. All nonsynonymous variants in MAPK pathway
genes are presented in Fig. S10.
To investigate possible mechanisms inducing somatic
mutations in T cells, we assessed mutational signature
analysis of the variants. We included both synonymous and
nonsynonymous single-nucleotide variants (SNVs) and
pooled the variants across CD4+ and CD8+ T cells per
group. Age-related signature 1 and defective mismatch-
repair signature 15 accounted for the majority of mutations
in both groups (Fig. 2C). Signature 29, which has been
linked to guanine damage, was specifically detected in AA.
For SNV types across different groups, the most frequent
alteration was C > T, a characteristic transversion type of
replication as well as of aging-associated mutagenesis
(Fig. S12A). Most nonsilent mutations were missense
(Fig. S12B) and there was no significant difference in muta-
tion types between groups (chi-squared test p value= 0.18).
CH mutations transmit to T cells
To understand timing of mutation acquisition, an integrative
analysis of our panel and previously published exome
sequencing data was performed. In our data, we found 15
nonsynonymous LP variants (occurring concurrently in
both CD4+ and CD8+ T cells) in 14 AA patients (Fig. 3A
and list of all variants in Table S3) with a mean allele
frequency of 11.4% [median 7.8%]. Older AA patients
inclined to have more LP variants (Fig. S13). With the
exception of NF1, these mutated genes have not been pre-
viously linked to CH. While CD4+ and CD8+ T cells
harbored many mutations in other genes linked to CH (e.g.,
DNMT3A, BCORL1, TERT, and LAMB4), they were not
concurrently detected in both T-cell fractions (Fig. 3B).
By reanalyzing WES data from Yoshizato et al. [13], we
investigated mutations in CH genes in T cells (Fig. S14).
Most frequent mutations in CD3− cells (T-cell depleted
fraction) were in DNMT3A, BCOR/BCORL1, and ASXL1
genes (found in 7, 6, and 6 patients, respectively). In some
cases, these mutations were also detected in CD3+ cells (T-
cell enriched fraction) of the same patient, but in other
instances they were present exclusively in CD3+ cells
(BCOR and BCORL1). When detected in CD3+ cells,
ASXL1 or DNMT3A mutations were always concurrently
present in CD3− cells, possibly due to a clonal advantage
exclusive to myeloid cells. JAK mutations (n= 2) were
found in both CD3− and CD3+ fractions. One STAT3
mutation (c.G1012T, p.V338F) was detected in CD3−
MNC with 3.3% VAF. This particular mutation was not
found in COSMIC v90 [39].
Index patients
To understand the effect of the variants on cell phenotype,
we performed paired single-cell RNA and TCRαβ sequen-
cing (scRNA+ TCRab-seq) analysis for samples from two
index patients. We chose patients who carried mutations on
JAK-STAT and MAPK signaling pathways and had avail-
able samples from different stages of disease.
Patient AA-4 was a 52-year-old previously healthy
female who was first hospitalized due to severe H1N1-
influenza infection, and afterward she gradually developed
worsening pancytopenia. The first bone marrow sample was
taken already at the time of H1N1 infection (because of
neutropenia), but the actual diagnosis of very severe AA
was made 17 months later (Fig. 4A). She was first treated
with cyclosporine A (CsA) and corticosteroids (CS) without
response. Two months later she was treated with equine
antithymocyte globulin (ATG)-based immunosuppression
which resulted in completely normalized blood counts after
4 months. Our first blood sample analyzed with scRNA+
TCRab-seq was obtained immediately prior the ATG
treatment and follow-up samples were received at 5 and
37 months. At the last sampling, the patient had been
without any immunosuppressive treatment with normal
blood counts for 25 months.
We found somatic STAT3 mutation p.Y640F in CD8+
cells of AA-4, which was confirmed to be restricted to one
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CD8+ T-cell clone (Vbeta 5.1) by flow cytometry sorting
and amplicon sequencing. The variant was not detected in
Vbeta 5.1− cells or in the other expanded CD8+ T-cell
clone (Vbeta 14+) (Fig. 4B). The VAF in sorted Vbeta 5.1
clone was 46%, indicating heterozygosity. The STAT3 p.
Y640F mutation was already detected with amplicon
sequencing in the bone marrow sample taken at the time of
influenza A infection (6% VAF), indicating infiltration of
mutated T cells in the bone marrow at the first appearance
of cytopenias. The VAF of the mutation in CD8+ T cells
decreased from 16 to 1% (analyzed by the immunogene
panel) after successful immunosuppression, consistent with
shrinkage of the expanded T-cell clone TCRVB05-01
(corresponding to Vbeta 5.1) with TCRb sequencing
(Fig. 4C).
scRNA+ TCRab-seq identified 21 different tran-
scriptomic clusters including seven CD8+ T-cell clusters





























































































AFig. 3 Somatic mutations
related to lympho-myeloid
clonal hematopoiesis in
immunogene panel data. A All
variants which were called from
both CD4+ and CD8+ T cells
in same patient and are hence
interpreted to be derived from
thymic precursors. MNV means
two or more single-nucleotide
variants in succession. B CD4+
and CD8+ specific variants in
genes previously reported to be
associated to CH in AA [13].
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from STAT3 mutated TCRBV05-01 clone (cluster 9) clus-
tered separately. We compared the gene expression profile
of this cluster to other CD8+ clusters and found cells to
express aberrantly cytotoxic genes (such as PRF1, NKG7,
DUSP1), genes associated with T-cell exhaustion (LAG3,
TIGIT), and cytokines included in cell migration (CCL3,
CCL4, CCL3L1, and CCL4L1, Fig. 5C).
At diagnosis, the TCRBV05-01 associated cluster
expressed the highest level of STAT3 and genes located
within 4 kb of its binding site (Fig. 5D, E). After treatment,
the TCRBV05-01 cluster diminished, concordant with the
decreased STAT3 VAF (Fig. 5F). The therapy also affected
the phenotype of the cluster, as cells lost expression of
multiple cytotoxic genes, including PRF1, GZMB, and
Fig. 4 AA-4 clinical timeline and somatic mutations. A Samples
analyzed with scRNA+ TCRab-seq from index patient AA-4 are
marked on the clinical timeline. In addition, BM biopsies were taken at
the time of influenza A infection and preceding severe AA diagnosis.
Blood counts are plotted in upper four panels (B-Hb= hemoglobin (g/l),
B-neut= neutrophils (E9/l), B-trom= thrombocytes (E9/l), E-retik=
reticulocyte percentage of erythrocytes). Corticosteroid (prednisolone)
and cyclosporine A (CyA) dosages (mg) are plotted in two panels
below. Timing of ATG treatment and influenza A infection are marked
with arrows. B Somatic STAT3 Y640F mutation was validated with
amplicon sequencing of sorted Vbeta 5.1+ fraction, but the mutation
was neither detected in Vbeta 14+ nor in Vbeta 5.1− fraction (in
sample 2). Picture of BAM files opened at variant site (chr17:42322464)
in Integrative Genomics Viewer. CMost expanded CTL clones of AA-4
at diagnosis (sample 1) and remission (sample 3), based on TCRb
sequencing. On the x axis are different time points and y axis shows the
frequency of each TCRb clone from whole CTL TCRb repertoire. At
diagnosis, there were two ~20% CTL clones, which significantly
diminished during immunosuppressive treatment. Vbeta 5.1 and
Vbeta 14 correspond to expanded T-cell clones TCRBV05-01 and
TCRBV19-01, respectively.
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Fig. 5 AA-4 scRNA+ TCRab-seq analysis. A Two-dimensional
UMAP projection of the transcriptomes of CD45+ lymphocyte cells
pooled from three time points from peripheral blood. A total of 24,000
cells are annotated in 21 distinct clusters, 7 of which can be annotated
as CD8+ T cells. *STAT3 mutated T-cell cluster. B Dot plot showing
the canonical markers used to annotate the clusters. C Volcano plot
showing differentially expressed genes between the TCRBV05-01
associated cluster (to the right, significant shown in red) against other
CD8+ clusters (to the left, significant shown in blue). D Violin plot
showing the scaled STAT3 expression in CD8+ clusters at diagnosis.
E Violin plot showing the score of genes having at least one occurence
of the transcription factor binding site within 4 kb of STAT3 binding
site at diagnosis. F The relative abundances of CD8+ clusters during
treatment. G Violin plot showing the significantly downregulated
cytotoxic genes (PRF1, GZMB, GZMH, GNLY, LYZ) and stable STAT3
expression in the TCRBV05-01 associated cluster.
Somatic mutations in lymphocytes in patients with immune-mediated aplastic anemia 1373
GNLY. STAT3 expression was not significantly altered
between time points (Fig. 5G).
Patient AA-3 was a 58-year-old previously healthy
female. She was diagnosed with severe AA after 2 years of
macrocytosis and mild thrombocytopenia. Initial treatment
included CsA and CS with no response, and 3 months after
the diagnosis she was treated with equine ATG-based
immunosuppression (Fig. 6A). No response was observed
by 6 months, and rabbit ATG-based immunosuppressive
therapy was administered. A year later (in summer 2014)
hemoglobin was normal, and platelets and neutrophils
temporarily improved. When the blood counts declined
Fig. 6 AA-3 clinical timeline
and somatic mutations.
A Samples analyzed with scRNA
+TCRab-seq are marked on the
clinical timeline. Blood counts
are plotted in upper four panels
(B-Hb= hemoglobin (g/l), B-
neut= neutrophils (E9/l), B-trom




A (CyA) dosages (mg) are plotted
in two panels below. Timing of
ATG treatments is marked with
arrows. B In AA-3, TCRBV04-
03 clone was expanding from
sample 1 (diagnosis) to relapse
(sample 3). On the x axis are
different time points and y axis
shows the frequency of each
TCRb clone from whole CTL
TCRb repertoire. C Amplicon
sequencing confirmed all
mutations in Vbeta 7.2+
(corresponding to TCRBV04-03)
fraction of CD8+ T cells. y axis
shows variant allele frequencies
within Vbeta 7.2+ CD8+ T cells
at different time points (shown at
x axis). D Possible subclonal
architecture of the mutations.
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during the second year, the second remission was achieved
with the reinitiation of CsA and CS; since then, she has
continued on low-dose immunosuppression with moderate
thrombocytopenia. The first sample was obtained before
first ATG, the second sample after second ATG (before
treatment response), and the third before the retreatment at
the relapse.
Patient AA-3 had somatic mutations in several genes,
including KRAS, NFATC2, PTPN22, TNFAIP3, and
JAGN1. KRAS A146P, JAGN1 T473A, and TNFAIP3
D212fs mutations were predicted to be pathogenic, and
same KRAS mutation has been found in several hematologic
neoplasms (genomic mutation ID in COSMIC v91:
COSV55541748). Similarly to AA-4, these mutations were
confirmed to be restricted to a single CD8+ T-cell clone
(Vbeta 7.2), as the variants were not detected in sorted
monocytes, B cells, or Vbeta 7.2− T cells. Vbeta 7.2 clone,
corresponding to TCRBV04-03 in TCRb deep sequencing,
increased despite immunosuppressive treatment (Fig. 6B).
VAFs in sorted Vbeta 7.2 clone from sample 3 and addi-
tional sample taken a year later are shown in Fig. 6C. An
additional fourth sample was only used for validation of
variants with amplicon sequencing, which revealed a pos-
sible subclonal architecture, as presented in Fig. 6D.
In single-cell analysis of this patient’s CD45+ lympho-
cyte cells from the bone marrow samples at three time
points, we identified 21 different clusters including seven
CD8+ T-cell clusters but only two CD4+ T clusters
(Fig. 7A, B). We identified 350 cells with matching TCRb
nucleotide sequence to the TCRBV04-03. Most of the cells
from the clone were CD8+ terminally differentiated effec-
tor memory cells (TEMRA), supporting the cytotoxic role of
the TCRBV04-03 clone (Fig. 7C).
The TCRBV04-03 clone increased after the CsA, CS,
and repeated ATG administration, and it was largest in the
relapse sample (4.8% of the whole CD8+ repertoire,
Fig. 7D). Similarly, the phenotype of the TCRBV04-03
clone changed from diagnosis to relapse (Fig. 7C, E).
To understand the effect of the somatic mutations on the
phenotype of the TCRBV04-03 clonotype, we performed
differential expression analysis between the TEMRA cells,
comparing the cells from the TCRBV04-03 clonotype
against the other cells in TEMRA cluster. In the relapse
sample, the number of differentially expressed genes
between the TCRBV04-03 clonotype in comparison to
other TEMRA cells was the highest compared to other sam-
ples (56 genes up in TCRBV04-03 clonotype and 77 genes
up in other TEMRA cells, genes listed in Table S7). Several
genes associated with the immune response such as STAT4,
NFKB1, and IFNGR1 were upregulated in the TCRBV04-
03 clonotype (Fig. 7F). In gene set enrichment analysis, the
upregulated pathways included type I interferon production,
NF-kappaB signaling, and lymphocyte activation (Fig. 7G).
Discussion
Accumulation of somatic mutations is inherent in normal
cell division and aging. Mutations can lead to abnormal cell
function and uncontrolled cell proliferation, as is well
established in cancer. Recently, it has also been shown that
somatic mutations occur in healthy human tissues [40–43]
and can play a role in the pathogenesis of other non-
malignant diseases [44]. In the current work, we addressed
the key questions of somatic mutations in T cells in patients
with immune-mediated AA: in which cell subset they occur,
at which state of immune cell development they emerge,
which genes and pathways are affected, and correlation with
clinical findings.
By gene panel sequencing of T cells, we discovered that
somatic variants in immune-related genes are strikingly
common in T cells. The mutation burden in CD8+ T cells
was higher than in CD4+ T cells. This observation is in line
with previous findings [21, 22, 24] and has both technical and
biological explanations. CD8+ T cells expand to large clones
[45], especially following strong antigen stimuli such as EBV
and CMV infections [46–48]. During rapid proliferation cells
are more susceptible to mutations. Larger T-cell clones have
higher VAFs, which facilitates mutation detection. However,
in our data, the mutation burden correlated with the T-cell
clonality within AA patients’ CD8+ T cells but not in healthy
CD8+ T cells. This observation implies that a technical
detection threshold could not alone explain higher mutation
burden in CD8+ T cells of AA patients.
In accordance with our previous findings [21, 22], we
were able to confirm that CD8+ specific somatic mutations
were restricted to single T-cell clones, indicating post-thymic
emergence. We were not able to study the clonal architecture
of somatic variants in the whole cohort, as the majority of the
variants had low VAFs and may have occurred in different T-
cell clones. Thus, the hierarchical ordering of variants based
on VAFs does not necessarily reflect the true order of
mutation appearance, as other factors, such as antigen-driven
expansion of T cells, may distort the hierarchy. The clonal
structure of mutations have been recently studied in myeloid
malignancies with single-cell DNA sequencing [49] and that
approach could elucidate the role and order of different
mutations in T cells as well.
We also showed that mutations in genes related to CH
are common in T cells, and CH mutation transmission to
T cells was frequently observed in the exome sequencing
dataset of AA patients’ CD3+ and CD3− MNCs [13]. The
lack of sequencing data from myeloid compartment dis-
tinctly limits our analysis. Previously, it has been shown
that CH mutations are more rare in T cells compared to
myeloid cells [50–52], but as the majority of publications
on CH are based on whole blood or total MNC fraction
sequencing, the mutation-specific patterns and prevalence
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of CH-related mutations in T cells remain to be conclusively
defined.
In immune-mediated AA, we found that T-cell somatic
mutations were especially frequent in the JAK-STAT and
MAPK pathways. It should be noted that healthy controls
also harbored mutations in both pathways, which may
implicate that mutations in these pathways may be
beneficial to T cells in general. Both of these pathways are
important for T-cell development and function. The JAK-
STAT pathway plays a central role in cytokine signaling
transmitting activation and proliferation signals in T cells
[53]. MAPK pathway is a major pathway induced by TCR
stimulation [54] and it also regulates apoptosis [55]. How-
ever, with our panel, we were only able to analyze
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mutations in 2533 preselected genes, and the full spectrum
of somatic mutations in T cells needs to be studied in future
with exome or whole genome sequencing.
To address the effect of somatic mutations on cell phe-
notype, we combined single-cell RNA sequencing with
TCRab sequencing. STAT3 p.Y640F mutated CD8+ T cells
had a strikingly altered immunophenotype compared to
other CD8+ T cells, forming their own unique phenotype
cluster. The clone also showed higher expression of STAT3
target genes, which is consistent with previous studies
showing STAT3 activation following p.Y640F mutation in
LGL leukemia, anaplastic large cell lymphoma, inflamma-
tory hepatocellular adenomas, and murine hematopoietic
stem cells [27, 56–58]. STAT3 has been shown to mediate
effector T-cell resistance to suppression in patients with
type 1 diabetes [59].
STAT3 mutated cells had highly cytotoxic immune phe-
notype similarly as KRAS mutated T cells in the other AA
index patient. The treatment response in these two patients
was different and correlated well with findings in the clone
size and phenotype. Thus, our results suggest that immuno-
suppressive treatment may alter not only the clone size but
also the cytotoxic function of mutated CD8+ T cells, and that
these changes may be linked to clinical outcomes. To gen-
eralize our results and to study effect of different mutations
on clinical outcomes, a bigger cohort of AA patients would
be needed with detailed clinical information available.
As the antigen target in immune-mediated AA is still
unknown, we were not able to test the autoreactivity of
clonal T cells. It is also undetermined whether the somatic
mutations are initial drivers or secondary events following
autoantigen-driven clonal expansions [60]. However, as
both in our study and previous studies [21, 26] it has been
shown that mutated T-cell clones persist for several years,
they may maintain the aberrant immune responses. Growing
evidence suggests that in myeloid cells, somatic mutations
are associated with inflammatory phenotypes and increased
risk for cardiovascular diseases [61–63]. Besides, donor CH
may be related to enhanced adaptive immune response in
bone marrow transplant recipients, as recipients with CH
have lower relapse rate but higher rates for graft-versus-host
disease [64]. Furthermore, Fraietta et al. showed that a
TET2-deficient CAR-T cell clone had less T-cell exhaustion
in response to stimulus and killed tumor cells more effi-
ciently [65].
In conclusion, somatic mutations in T cells particularly in
the JAK-STAT and MAPK pathways are common in
patients with immune-mediated AA. Mutations are asso-
ciated with T-cell clonality but not distinctly with age,
differentiating them from typical CH mutations. Our find-
ings imply that somatic mutations are one putative
mechanism of aberrant T-cell activation. Treatments that
target the mutated clones could have therapeutic value in
immune-mediated AA.
Data availability
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